PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1397300
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1397300
Precision medicine is an emerging approach to preventive health and disease treatment that takes into account individual variations in genes, lifestyle, and environment. It enables doctors and physicians to tailor therapies to an individual's unique genetic profile, offering personalized treatment options. The Precision Medicine Initiative (PMI) was introduced to expand precision medicine's reach to all diseases, with the goal of enrolling over one million volunteers. The initiative focuses on research at the intersection of genetics, lifestyle, environment, and disease management, aiming to advance healthcare by prolonging health and improving disease treatment.
The short-term objectives of the Precision Medicine Initiative include targeted cancer therapy, the use of combination therapies, and understanding drug resistance. In the long term, the initiative aims to create a cohort of one million American volunteers who will contribute genetic data, lifestyle information, and biological samples linked to electronic health records. This extensive database will drive pharmacogenomics research and lay a solid scientific foundation for precision medicine in treating various diseases.
Several factors contribute to the growth of the precision medicine market, including:
The precision medicine market is segmented based on application, including oncology drugs, immunology, neurology, cardiology, infectious diseases, and others. The oncology segment holds a significant share of the market, while immunology is expected to witness impressive growth.
North America leads the global precision medicine market, with substantial investments in precision medicine research and development in the United States. While initial funding is primarily focused on oncology, research is expected to expand into other applications. As economically developing regions like Asia-Pacific catch up, significant market growth is anticipated in these regions over the forecast period.
Prominent companies in the global precision medicine market include: F Hoffmann-La Roche AG, Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN, Quest Diagnostics, Laboratory Corporation of America Holdings, Novartis AG, AstraZeneca, Bristol-Myers Squibb, and Eli Lilly And Company. These companies are actively expanding their product pipelines through new molecule applications and collaborations. Strategies such as mergers, acquisitions, and industry-academia partnerships are being employed to commercialize molecules and sequencing techniques, influencing market trends.